Payment overview · 2025
General Payments
$929.60
52 reported records · 21 companies
Healthcare provider profile · identity verified
Jeffrey S Mayfield, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BENTON, AR · NPI 1184697203
Verified facts
What the public records show
CMS Open Payments records show Jeffrey S Mayfield, M.D. received $929.60 in general payments during 2025 across 52 reported records.
PFIZER INC. accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $206.00 | 22.2% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $86.24 | 9.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $82.32 | 8.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $75.75 | 8.2% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.79 | 4.9% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $41.81 | 4.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.64 | 4.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.23 | 4.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $36.72 | 4.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $35.77 | 3.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.64 | 3.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.34 | 3.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $27.05 | 2.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.12 | 2.7% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $24.30 | 2.6% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $22.65 | 2.4% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.80 | 2.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.75 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.33 | 1.8% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $15.83 | 1.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.52 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $929.60 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $137.63 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $122.96 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $107.11 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $82.32 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $68.37 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $68.37 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $68.37 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.84 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $45.79 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $41.81 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $38.64 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37.23 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $35.77 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $30.52 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $28.64 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.34 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.34 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.26 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.26 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $27.05 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 93 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 156 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
80 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
156 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 821 | 208 |
| Levothyroxine Sodium | Levothyroxine Sodium | 568 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 516 | 126 |
| Gabapentin | Gabapentin | 492 | 110 |
| Omeprazole | Omeprazole | 455 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 411 | 104 |
| Lisinopril | Lisinopril | 406 | 113 |
| Tramadol Hcl | Tramadol Hcl | 298 | 68 |
| Potassium Chloride | Potassium Chloride | 276 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 57 |
| Metformin Hcl | Metformin Hcl | 248 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 247 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 245 | 66 |
| Diclofenac Sodium | Diclofenac Sodium | 229 | 54 |
| Losartan Potassium | Losartan Potassium | 228 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 225 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 52 |
| Metformin Hcl Er | Metformin Hcl | 221 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 216 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 43 |
| Prednisone | Prednisone | 215 | 163 |
| Trazodone Hcl | Trazodone Hcl | 214 | 47 |
| Furosemide | Furosemide | 209 | 57 |
| Simvastatin | Simvastatin | 206 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 203 | 53 |
| Mirtazapine | Mirtazapine | 194 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 170 | 35 |
| Glimepiride | Glimepiride | 170 | 31 |
| Clonazepam | Clonazepam | 164 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 22 |
| Allopurinol | Allopurinol | 162 | 40 |
| Ozempic | Semaglutide | 156 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 38 |
| Montelukast Sodium | Montelukast Sodium | 140 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 139 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 138 | 112 |
| Bupropion Xl | Bupropion Hcl | 133 | 27 |
| Meloxicam | Meloxicam | 133 | 32 |
| Sertraline Hcl | Sertraline Hcl | 129 | 31 |
| Cefdinir | Cefdinir | 126 | 95 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 121 | 27 |
| Alprazolam | Alprazolam | 120 | 27 |
| Glipizide Er | Glipizide | 119 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 30 |
| Buspirone Hcl | Buspirone Hcl | 114 | 23 |
| Estradiol | Estradiol | 105 | 25 |
| Azithromycin | Azithromycin | 103 | 87 |
| Propranolol Hcl | Propranolol Hcl | 102 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 102 | 20 |
| Promethazine Hcl | Promethazine Hcl | 98 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 96 | 76 |
| Ezetimibe | Ezetimibe | 96 | 20 |
| Eliquis | Apixaban | 93 | 16 |
| Glipizide | Glipizide | 89 | 19 |
| Carvedilol | Carvedilol | 88 | 23 |
| Clonidine Hcl | Clonidine Hcl | 86 | 42 |
| Methocarbamol | Methocarbamol | 86 | 43 |
| Mounjaro | Tirzepatide | 85 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 82 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 14 |
| Synthroid | Levothyroxine Sodium | 80 | 15 |
| Lorazepam | Lorazepam | 78 | 26 |
| Pregabalin | Pregabalin | 77 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 27 |
| Ipratropium Bromide | Ipratropium Bromide | 74 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 18 |
| Atenolol | Atenolol | 72 | 16 |
| Clindamycin Hcl | Clindamycin Hcl | 71 | 53 |
| Jardiance | Empagliflozin | 70 | 16 |
| Aripiprazole | Aripiprazole | 69 | 12 |
| Januvia | Sitagliptin Phosphate | 69 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 50 |
| Donepezil Hcl | Donepezil Hcl | 66 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 65 | 13 |
| Alendronate Sodium | Alendronate Sodium | 64 | 14 |
| Lamotrigine | Lamotrigine | 62 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 20 |
| Methylprednisolone | Methylprednisolone | 58 | 47 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 57 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 54 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 15 |
| Memantine Hcl | Memantine Hcl | 50 | suppressed |
| Sucralfate | Sucralfate | 50 | 18 |
| Celecoxib | Celecoxib | 49 | 16 |
| Benazepril Hcl | Benazepril Hcl | 48 | 11 |
| Famotidine | Famotidine | 46 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 16 |
| Terbinafine Hcl | Terbinafine Hcl | 42 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Fluconazole | Fluconazole | 40 | 21 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 33 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 12 |
| Ramipril | Ramipril | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Mupirocin | Mupirocin | 34 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Verapamil Er | Verapamil Hcl | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 13 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 32 | suppressed |
| Cephalexin | Cephalexin | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Eszopiclone | Eszopiclone | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 14 |
| Metronidazole | Metronidazole | 30 | 23 |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Nystatin | Nystatin | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Ketoconazole | Ketoconazole | 28 | 18 |
| Olanzapine | Olanzapine | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Primidone | Primidone | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 18 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 18 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | 11 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 17 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Progesterone | Progesterone, Micronized | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tresiba | Insulin Degludec | 12 | suppressed |
| Vimpat | Lacosamide | 12 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $929.60 · 52 records | PFIZER INC. | ABRYSVO, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, Dyanavel XR, ELIQUIS, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, Senza, TRINTELLIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, XYOSTED, YUPELRI, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error